Company intelligence / Profile preview

Alithea Bio

Freiburg im Breisgau, Baden-Württemberg, Germanyalithea-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Alithea Bio provides advanced immunopeptidomics services using proprietary high-sensitivity mass spectrometry and machine learning to support the development of precision immunotherapies. Their technologies enable rapid identification and quantification of neoepitopes, gene-derived epitopes, and drug-induced antigens presented on HLA complexes. This accelerates target validation, toxicity profiling, and IND-enabling studies for biopharma clients working on cancer vaccines, TCR therapies, antibody drugs, and related modalities.

Therapeutic areas: OncologyImmunology
Modalities: Neoantigen-targeted therapies (e.g., cancer vaccines)TCR-engineered T cell therapyT cell engagersTCR mimic antibodies
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Alithea Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alithea Bio.

Explore the full profile